On Friday 19 June, Glenmark Pharmaceuticals had received manufacturing and marketing approval from India’s drug regulator. Fabiflu is India’s first oral antiviral vaccine for the treatment of mild and moderate coronavirus patients. On Saturday the company said that this vaccine would be available from the evening and by next week across the country.
FabiFlu is the first oral Favipiravir-approve medication. The company has also got approval under the emergency category. This drug will be available at hospitals and also chemist shops. It will sell under a medical prescription.
How to use:-
Each tablet of 200 mg costs Rs.103 and a strip containing 34 tablets have been priced at Rs.3500. On the First Day, the patient will administer 18 tablets of 200 mg each, 9 tablets in the morning, and also 9 tablets in the evening. From the second Day with 4 tablets of 200 mg each in the morning and evening. Medicine can be administered to patients between the age of 18 to 75.
In India, 70 to 80% of COVID-19 patients are from mild and moderate symptoms. Therefore, this drug has approved for these symptoms. A patient of this category need not be admitted to the hospital. They can also stay at home.
Company executives said that this drug will help in reducing the pressure on hospitals. Glenmark is taking care of end to end processes of this medication starting from manufacturing API.
In India, this drug clinical trial is on for 150 patients. The company is also planning for a combination trial for COVID-19 treatment.
This vaccine has also used in Russia, Japan, and also in China for the treatment of coronavirus patients. It has also approved successfully.
The drug will be available both at hospitals and also chemist shop but it will be sold strictly only on doctor’s prescription.
Visit more about it on guzubit.com